Fractyl Health, Inc. Common Stock Earnings Recaps
Q1 2026
May 13, 2026
Shares fell 4.6% as investors reacted to cautious outlook signals, including slower-than-expected momentum in the pivotal trial enrollment and an extended timeline to top-line data, raising concerns about near-term value realization.
Key takeaways
- The pivotal REMAIN-1 trial completed randomization in February with over 300 participants across 30+ U.S. sites, but the market appears concerned about the pace and timing of data readout.
- Co-primary endpoints focus on mitigating weight regain at 6 months post-tirzepatide discontinuation and maintaining ≥5% weight loss at 52 weeks; top-line results are expected in early Q4 2026.
- Participant retention remains high (>90%), and adverse events align with prior studies, supporting trial continuity but offering no immediate upside.
- Management reaffirmed no planned capital raise before pivotal data, yet the extended timeline limits visibility on near-term catalysts.
- FDA feedback continues to favor a moderate-risk device classification, with submission anticipated late Q4 2026 contingent on the 6-month data.
Q3 2025
Nov 14, 2025
Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.
Key takeaways
- Successfully reported randomized double-blind data indicating sustained weight loss in Revita-treated patients post-GLP-1 therapy, a critical advancement in obesity treatment.
- Clinical programs are ahead of schedule, with over 60% of patient randomizations for the pivotal REMAIN one cohort completed.
- Upcoming catalysts include six-month data from multiple cohorts and pivotal study results expected in 2026, positioning Revita for potential transformative impact in metabolic medicine.
- Real-world studies further validate Revita's efficacy, showing significant weight loss and reductions in HbA1c in patients with type 2 diabetes over extended follow-up periods.